Skip to main content
. 2023 Mar 21;21:29. doi: 10.1186/s12958-023-01082-w

Table 2.

Clinical outcomes

Strategy or outcome G-CSF group Control group
Patients completing the study 50 patients 49 patients
Conventional infertility treatments in initial and second cycles with or without G-CSF priming
 Live deliveries (% per patient) 3 a (6.0%) 0 (0%)
IVF/ICSI and fresh ET
 Ovarian stimulation (OS) 47 patients 49 patients
 No follicular development induced (% per OS) 0 (0%) 1 (2.0%)
 Numbers of follicles (≥ 16 mm) on the hCG day 4.2 ± 2.9 3.0 ± 1.7
 Serum E2 concentrations (pg/mL) on the hCG day 1820 ± 1200 1350 ± 840
 Successful oocyte retrievals (% per OS) 47 (100%) 48 (98%)
 No ET for lack of transferrable embryos (% per OS) 2 (4.3%) 4 (8.2%)
 Fresh ETs (% per OS) 45 (96%) 44 (90%)
 Cryopreservation of redundant blastocysts possible (% per OS) 25 (53%) b 12 (24%)
 Clinical pregnancies (% per OS) 14 (30%) c 6 (12%)
 Ongoing pregnancies (% per OS) 12 (26%) d 5 (10%)
 Live deliveries (% per OS) 9 (19%) 5 (10%)
Cryopreserved ET 21 cycles 14 cycles
 Clinical pregnancies (% per cryopreserved ET) 6 (29%) 4 (29%)
 Live deliveries (% per cryopreserved ET) 4 (19%) 2 (14%)
Numbers of cumulative live deliveries (% per patient) 16 (32%) e 7 (14%)

a All 3 patients conceived with spontaneous ovulation following initial G-CSF priming

bP < 0.01 vs. control group, chi-squared test; relative risk (RR) = 3.5; 95% confidence interval (CI), 1.5–8.3

cP < 0.05 vs. control group, chi-squared test; RR = 3.0; 95% CI, 1.1–8.8

dP < 0.05 vs. control group, chi-squared test; RR = 3.0; 95% CI, 1.0–9.4

eP < 0.05 vs. control group, chi-squared test; RR = 2.8; 95% CI, 1.04–7.7